If you have been reading about Melanotan II and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-03. Numbers and descriptions here follow the published literature rather than marketing material.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
== Anti-fouling coatings == Marine Biofouling is described as the undesirable buildup of microorganisms, plants, and animals on artificial surfaces immersed in water. Significant buildup of biofouling on marine vessels can be problematic. Traditionally, biocides, a chemical substance or microorganism that can control the growth of harmful organisms by chemical or biological means, are used to prevent marine biofouling. Biocides can be either synthetic, such as tributyltin (TBT), or natural, which are derived from bacteria or plants. TBT was historically the main biocide used for anti-fouling coatings, but more recently TBT compounds have been considered toxic chemicals which have negative effects on humans and the environment, and have been banned by the International Maritime Organization. The early design of anti-fouling coatings consisted of the active ingredients (e.g. TBT) dispersed in the coating in which they "leached" into the seawater, killing any microbes or other marine life that had attached to the ship. The release rate for the biocide tended to be uncontrolled and often rapid, leaving the coating only effective for 18 to 24 months before all the biocide leached out of the coating.
==== Displacement and collapse of coastal fishing livelihoods ==== Displacement has been a persistent feature of the conflict. Around 3.65 million Yemenis are estimated to be internally displaced, and many households have moved multiple times as fighting shifted between regions. These people often end up in overcrowded camps or informal settlements, or are absorbed into host communities whose resources and services are already under strain, which can limit displaced people access to shelter, education, health care and employment. On the Red Sea coast, these patterns of displacement intersect with the decline of artisanal fishing. Before the war, fishing was the country’s second largest export sector after oil and gas and an important pillar of local livelihoods, providing work for more than half a million people and supporting an estimated 1.7 million. From 2015 onwards, airstrikes, naval attacks and blockades targeted fishing boats, landing sites and coastal settlements, which, combined with security restrictions and interception at sea, made fishing increasingly dangerous. Because of this, in some coastal areas only about half of the fishermen were able to continue going to sea, while in others the residents have completely abandoned their homes following repeated attacks. Data indicate that the average monthly income of the fishermen still operating fell by around 45 percent, while the cost of boats and engines rose sharply as the currency weakened and imports became more expensive.
== Career == In early 1964, Sarkar presented his PhD research at the Federation of American Societies for Experimental Biology (FASEB) meeting in Chicago, where he was approached by Andrew Sass-Kortsak, a clinician specializing in Wilson's disease at Toronto's Hospital for Sick Children. Sass-Kortsak, then leading the hospital's Genetic Metabolic Program, sought a basic scientist to join his team and offered Sarkar a staff scientist position. This role included start-up funding and a dedicated laboratory in a newly constructed wing of the hospital. Shortly after, Sarkar received a cross-appointment to the University of Toronto's Department of Biochemistry. Sarkar began attending clinical Grand Rounds with Sass-Kortsak and visited Wilson's disease patients in hospital wards. His research shifted toward metal-related disorders, driven by his expertise in biophysical studies of metal-protein interactions and metal transport. Collaborating with Sass-Kortsak, Sarkar pioneered multidisciplinary research at SickKids, bridging basic science and clinical medicine to foster a collaborative institutional environment. In 1990, he was appointed head of the Division of Biochemistry Research at SickKids.
Sources: en.wikipedia.org
== Chemistry == Chemical investigations of petroleum ether and chloroform extracts led to the isolation of β-sitosterol, ursolic acid, oleanolic acid, 3-epiursolic acid, 3-epioleanolic acid and minor triterpenoids of derivatives of ursolic acid and oleanolic acids. Chromatographic purification of the methanol extract yield two iridoid glucosides (verbenalin and hastatoside), a phenylpropanoid glycoside, verbascoside and β-sitosterol-D-glucoside. Hastatoside and verbenalin have sleep-promoting (soporific) properties. It also contains a monoterpene alcohol called verbenol. In another study, four compounds were isolated and identified as apigenin, 4'-hydroxywogonin, verbenalin, and hastatoside. Aucubin has also been found as one of the active constituents.
When diagnosed with myasthenia gravis, an individual can be stratified into distinct subgroups based on the clinical features and serological status, e.g., affected muscle group, age of onset, thymic abnormalities, and profile of serum autoantibodies. Based on the affected muscle group, people with myasthenia gravis can be sub-grouped into ocular myasthenia gravis or generalized myasthenia gravis. Ocular myasthenia gravis is characterized by exclusively ocular symptoms, droopy eyelids, or double vision. Generalized myasthenia gravis has muscle weakness with a variable combination of the bulbar, axial, or limb and respiratory muscles. People with myasthenia gravis can also be sub-grouped by the age of onset: juvenile-onset myasthenia gravis (onset age ≤ 18 years of age), early-onset MG (EOMG; 19–50 years of age), late-onset MG (LOMG; onset > 50 years of age), and very late-onset (VLOMG; onset age ≥ 65 years of age). The subgroup of the autoantibody profile includes AChR seropositive, MuSK seropositive, LRP4 seropositive, and agrin seropositive.
The general justifications for limiting free movement in TFEU article 45(3) are "public policy, public security or public health", and there is also a general exception in article 45(4) for "employment in the public service".
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.